Home The Word Brain My Amedeo FAQ Privacy About Flying Publisher   


COVID-19: Daily Top 10 Papers


  Ischemic Heart Disease

  Free Subscription


Articles published in JAMA

Retrieve available abstracts of 202 articles:
HTML format



Single Articles


    July 2021
  1. WILKINS JT, Lloyd-Jones DM
    Novel Lipid-Lowering Therapies to Reduce Cardiovascular Risk.
    JAMA. 2021;326:266-267.
    PubMed    


  2. MIKSENAS H, Januzzi JL Jr, Natarajan P
    Lipoprotein(a) and Cardiovascular Diseases.
    JAMA. 2021 Jul 8. pii: 2781946. doi: 10.1001/jama.2021.3632.
    PubMed    


    June 2021
  3. SATO T, Terada R, Ikeda T
    Effect of Restrictive or Liberal Blood Transfusion on Major Cardiovascular Events in Patients With Acute Myocardial Infarction and Anemia.
    JAMA. 2021;325:2505-2506.
    PubMed    


  4. DUCROCQ G, Simon T, Steg PG
    Effect of Restrictive or Liberal Blood Transfusion on Major Cardiovascular Events in Patients With Acute Myocardial Infarction and Anemia-Reply.
    JAMA. 2021;325:2506-2507.
    PubMed    


  5. SOLOMON MD, Nguyen-Huynh M, Leong TK, Alexander J, et al
    Changes in Patterns of Hospital Visits for Acute Myocardial Infarction or Ischemic Stroke During COVID-19 Surges.
    JAMA. 2021 Jun 2. pii: 2780794. doi: 10.1001/jama.2021.8414.
    PubMed    


    May 2021
  6. GOTTESMAN RF, Johansen MC
    Coronary Revascularization and Cognitive Decline: The Patient or the Procedure?
    JAMA. 2021;325:1941-1942.
    PubMed    


  7. OGATA H, Fukagawa M, Hirakata H, Kagimura T, et al
    Effect of Treating Hyperphosphatemia With Lanthanum Carbonate vs Calcium Carbonate on Cardiovascular Events in Patients With Chronic Kidney Disease Undergoing Hemodialysis: The LANDMARK Randomized Clinical Trial.
    JAMA. 2021;325:1946-1954.
    PubMed     Abstract available


  8. WHITLOCK EL, Diaz-Ramirez LG, Smith AK, Boscardin WJ, et al
    Association of Coronary Artery Bypass Grafting vs Percutaneous Coronary Intervention With Memory Decline in Older Adults Undergoing Coronary Revascularization.
    JAMA. 2021;325:1955-1964.
    PubMed     Abstract available


  9. JOSHI PH, de Lemos JA
    Diagnosis and Management of Stable Angina: A Review.
    JAMA. 2021;325:1765-1778.
    PubMed     Abstract available


    April 2021
  10. EL-BATTRAWY I, Behnes M, Akin I
    Depression and Incident Cardiovascular Disease.
    JAMA. 2021;325:1679-1680.
    PubMed    


  11. DAVIDSON KW, Pennells L, Di Angelantonio E
    Depression and Incident Cardiovascular Disease-Reply.
    JAMA. 2021;325:1680.
    PubMed    


  12. ANCHAN R, Cifu AS, Paul J
    Management of Acute Coronary Syndromes in Patients Without Persistent ST-Segment Elevation.
    JAMA. 2021;325:1556-1557.
    PubMed    


  13. RIGATELLI G, Zuin M
    Fractional Flow Reserve Treatment and Major Adverse Cardiac Events in Patients With Coronary Artery Disease.
    JAMA. 2021;325:1565.
    PubMed    


  14. SUD M, Fang J, Ko DT
    Fractional Flow Reserve Treatment and Major Adverse Cardiac Events in Patients With Coronary Artery Disease-Reply.
    JAMA. 2021;325:1565-1566.
    PubMed    


  15. KAMRAN H, Jneid H, Kayani WT, Virani SS, et al
    Oral Antiplatelet Therapy After Acute Coronary Syndrome: A Review.
    JAMA. 2021;325:1545-1555.
    PubMed     Abstract available


  16. WANG Y
    Omega-3 Fatty Acids Effect on Major Cardiovascular Events in Patients at High Cardiovascular Risk.
    JAMA. 2021;325:1333.
    PubMed    


  17. OLSHANSKY B, Bhatt DL, Chung MK
    Omega-3 Fatty Acids Effect on Major Cardiovascular Events in Patients at High Cardiovascular Risk.
    JAMA. 2021;325:1332-1333.
    PubMed    


  18. PARK KY, Park HK, Hwang HS
    Omega-3 Fatty Acids Effect on Major Cardiovascular Events in Patients at High Cardiovascular Risk.
    JAMA. 2021;325:1334.
    PubMed    


  19. WELTY F, Bistrian B, Driscoll D
    Omega-3 Fatty Acids Effect on Major Cardiovascular Events in Patients at High Cardiovascular Risk.
    JAMA. 2021;325:1333.
    PubMed    


  20. NISSEN SE, Lincoff AM, Nicholls SJ
    Omega-3 Fatty Acids Effect on Major Cardiovascular Events in Patients at High Cardiovascular Risk-Reply.
    JAMA. 2021;325:1334-1335.
    PubMed    


    March 2021
  21. SLOMSKI A
    Polypill Plus Aspirin Effective for Cardiovascular Disease Prevention.
    JAMA. 2021;325:1135.
    PubMed    


  22. FRIEDEN TR, Foti KE
    National Initiatives to Prevent Myocardial Infarction and Stroke.
    JAMA. 2021 Mar 12. pii: 2777651. doi: 10.1001/jama.2021.0905.
    PubMed    


  23. YOU SC, Gupta A, Krumholz HM
    Ticagrelor vs Clopidogrel for Patients With Acute Coronary Syndrome Undergoing Percutaneous Intervention-Reply.
    JAMA. 2021;325:890-891.
    PubMed    


  24. KIM HK, Kubica J, Jeong YH
    Ticagrelor vs Clopidogrel for Patients With Acute Coronary Syndrome Undergoing Percutaneous Intervention.
    JAMA. 2021;325:890.
    PubMed    


    February 2021
  25. KOLTE D, Libby P, Jang IK
    New Insights Into Plaque Erosion as a Mechanism of Acute Coronary Syndromes.
    JAMA. 2021 Feb 22. pii: 2776938. doi: 10.1001/jama.2021.0069.
    PubMed    


  26. PERAK AM, Lancki N, Kuang A, Labarthe DR, et al
    Associations of Maternal Cardiovascular Health in Pregnancy With Offspring Cardiovascular Health in Early Adolescence.
    JAMA. 2021;325:658-668.
    PubMed     Abstract available


  27. DANIELS SR
    Maternal Cardiovascular Health: A Critical Period for Offspring Lifetime Cardiovascular Health?
    JAMA. 2021;325:630-631.
    PubMed    


  28. DUCROCQ G, Gonzalez-Juanatey JR, Puymirat E, Lemesle G, et al
    Effect of a Restrictive vs Liberal Blood Transfusion Strategy on Major Cardiovascular Events Among Patients With Acute Myocardial Infarction and Anemia: The REALITY Randomized Clinical Trial.
    JAMA. 2021;325:552-560.
    PubMed     Abstract available


  29. KHATANA SAM, Venkataramani AS, Nathan AS, Dayoub EJ, et al
    Association Between County-Level Change in Economic Prosperity and Change in Cardiovascular Mortality Among Middle-aged US Adults.
    JAMA. 2021;325:445-453.
    PubMed     Abstract available


  30. WEEKS WB, Weinstein JN
    Economic Prosperity and Cardiovascular Mortality: Further Evidence That All Policy Is Health Policy.
    JAMA. 2021;325:439-440.
    PubMed    


    January 2021
  31. LOPES RD, Macedo AVS, de Barros E Silva PGM, Moll-Bernardes RJ, et al
    Effect of Discontinuing vs Continuing Angiotensin-Converting Enzyme Inhibitors and Angiotensin II Receptor Blockers on Days Alive and Out of the Hospital in Patients Admitted With COVID-19: A Randomized Clinical Trial.
    JAMA. 2021;325:254-264.
    PubMed     Abstract available


    December 2020
  32. SLOMSKI A
    Empagliflozin Cuts Cardiovascular Deaths in Advanced Heart Failure.
    JAMA. 2020;324:2476.
    PubMed    


  33. HARSHFIELD EL, Pennells L, Schwartz JE, Willeit P, et al
    Association Between Depressive Symptoms and Incident Cardiovascular Diseases.
    JAMA. 2020;324:2396-2405.
    PubMed     Abstract available


  34. PATEL MM, Uyeki TM
    Influenza Vaccine for Patients With High-risk Cardiovascular Disease.
    JAMA. 2020 Dec 4. pii: 2773988. doi: 10.1001/jama.2020.23948.
    PubMed    


  35. VARDENY O, Kim K, Udell JA, Joseph J, et al
    Effect of High-Dose Trivalent vs Standard-Dose Quadrivalent Influenza Vaccine on Mortality or Cardiopulmonary Hospitalization in Patients With High-risk Cardiovascular Disease: A Randomized Clinical Trial.
    JAMA. 2020 Dec 4. pii: 2773989. doi: 10.1001/jama.2020.23649.
    PubMed     Abstract available


    November 2020
  36. KRIST AH, Davidson KW, Mangione CM, Barry MJ, et al
    Behavioral Counseling Interventions to Promote a Healthy Diet and Physical Activity for Cardiovascular Disease Prevention in Adults With Cardiovascular Risk Factors: US Preventive Services Task Force Recommendation Statement.
    JAMA. 2020;324:2069-2075.
    PubMed     Abstract available


  37. O'CONNOR EA, Evans CV, Rushkin MC, Redmond N, et al
    Behavioral Counseling to Promote a Healthy Diet and Physical Activity for Cardiovascular Disease Prevention in Adults With Cardiovascular Risk Factors: Updated Evidence Report and Systematic Review for the US Preventive Services Task Force.
    JAMA. 2020;324:2076-2094.
    PubMed     Abstract available


  38. JIN J
    Counseling on Healthy Diet and Physical Activity to Prevent Cardiovascular Disease.
    JAMA. 2020;324:2114.
    PubMed    


  39. SMILOWITZ NR, Berger JS
    Cardiovascular Risk Assessment for Noncardiac Surgery-Reply.
    JAMA. 2020;324:2106-2107.
    PubMed    


  40. GRASSHOFF C, Magunia H
    Cardiovascular Risk Assessment for Noncardiac Surgery.
    JAMA. 2020;324:2105-2106.
    PubMed    


  41. KHAN SS, Greenland P
    Comprehensive Cardiovascular Health Promotion for Successful Prevention of Cardiovascular Disease.
    JAMA. 2020;324:2036-2037.
    PubMed    


  42. SHARMA G, Martin SS, Blumenthal RS
    Effects of Omega-3 Fatty Acids on Major Adverse Cardiovascular Events: What Matters Most: the Drug, the Dose, or the Placebo?
    JAMA. 2020 Nov 15. pii: 2773118. doi: 10.1001/jama.2020.22387.
    PubMed    


  43. NICHOLLS SJ, Lincoff AM, Garcia M, Bash D, et al
    Effect of High-Dose Omega-3 Fatty Acids vs Corn Oil on Major Adverse Cardiovascular Events in Patients at High Cardiovascular Risk: The STRENGTH Randomized Clinical Trial.
    JAMA. 2020 Nov 15. pii: 2773120. doi: 10.1001/jama.2020.22258.
    PubMed     Abstract available


  44. SUD M, Han L, Koh M, Austin PC, et al
    Association Between Adherence to Fractional Flow Reserve Treatment Thresholds and Major Adverse Cardiac Events in Patients With Coronary Artery Disease.
    JAMA. 2020 Nov 13. pii: 2773127. doi: 10.1001/jama.2020.22708.
    PubMed     Abstract available


  45. BACH RG
    Physiology-Based Revascularization Decisions and Improved Clinical Outcomes Following Percutaneous Coronary Interventions.
    JAMA. 2020 Nov 13. pii: 2773126. doi: 10.1001/jama.2020.22998.
    PubMed    


    October 2020
  46. SLOMSKI A
    Colchicine Reduces Cardiovascular Events in Chronic Coronary Disease.
    JAMA. 2020;324:1599.
    PubMed    


  47. BATES ER
    Net Adverse Clinical Events With Antiplatelet Therapy in Acute Coronary Syndromes.
    JAMA. 2020;324:1613-1615.
    PubMed    


  48. YOU SC, Rho Y, Bikdeli B, Kim J, et al
    Association of Ticagrelor vs Clopidogrel With Net Adverse Clinical Events in Patients With Acute Coronary Syndrome Undergoing Percutaneous Coronary Intervention.
    JAMA. 2020;324:1640-1650.
    PubMed     Abstract available


    August 2020
  49. PEREIRA NL, Farkouh ME, So D, Lennon R, et al
    Effect of Genotype-Guided Oral P2Y12 Inhibitor Selection vs Conventional Clopidogrel Therapy on Ischemic Outcomes After Percutaneous Coronary Intervention: The TAILOR-PCI Randomized Clinical Trial.
    JAMA. 2020;324:761-771.
    PubMed     Abstract available


  50. MOLITERNO DJ, Smyth SS, Abdel-Latif A
    CYP2C19 Genotyping to Guide Antiplatelet Therapy After Percutaneous Coronary Interventions: One Size Rarely Fits All.
    JAMA. 2020;324:747-749.
    PubMed    


    July 2020
  51. JABBAR A, Ingoe L, Junejo S, Carey P, et al
    Effect of Levothyroxine on Left Ventricular Ejection Fraction in Patients With Subclinical Hypothyroidism and Acute Myocardial Infarction: A Randomized Clinical Trial.
    JAMA. 2020;324:249-258.
    PubMed     Abstract available


  52. DHRUVA SS, Mortazavi BJ, Desai NR
    Intravascular Microaxial Left Ventricular Assist Device vs Intra-aortic Balloon Pump for Cardiogenic Shock-Reply.
    JAMA. 2020;324:303-304.
    PubMed    


  53. RAVN HB, Helgestad OKL, Moller JE
    Intravascular Microaxial Left Ventricular Assist Device vs Intra-aortic Balloon Pump for Cardiogenic Shock.
    JAMA. 2020;324:302-303.
    PubMed    


  54. RIZZO JA, Dove H
    Intravascular Microaxial Left Ventricular Assist Device vs Intra-aortic Balloon Pump for Cardiogenic Shock.
    JAMA. 2020;324:303.
    PubMed    


  55. SMILOWITZ NR, Berger JS
    Perioperative Cardiovascular Risk Assessment and Management for Noncardiac Surgery: A Review.
    JAMA. 2020;324:279-290.
    PubMed     Abstract available


  56. NISSEN SE, Bakaeen FG
    Coronary Revascularization Strategies: Making Sense of Sparse, Limited-Quality Data.
    JAMA. 2020;324:154-156.
    PubMed    


  57. GAUDINO M, Benedetto U, Fremes S, Ballman K, et al
    Association of Radial Artery Graft vs Saphenous Vein Graft With Long-term Cardiovascular Outcomes Among Patients Undergoing Coronary Artery Bypass Grafting: A Systematic Review and Meta-analysis.
    JAMA. 2020;324:179-187.
    PubMed     Abstract available


  58. ORKABY AR, Driver JA, Ho YL, Lu B, et al
    Association of Statin Use With All-Cause and Cardiovascular Mortality in US Veterans 75 Years and Older.
    JAMA. 2020;324:68-78.
    PubMed     Abstract available


    June 2020
  59. HADAYA J, Benharash P
    Extracorporeal Membrane Oxygenation.
    JAMA. 2020;323:2536.
    PubMed    


  60. KIM BK, Hong SJ, Cho YH, Yun KH, et al
    Effect of Ticagrelor Monotherapy vs Ticagrelor With Aspirin on Major Bleeding and Cardiovascular Events in Patients With Acute Coronary Syndrome: The TICO Randomized Clinical Trial.
    JAMA. 2020;323:2407-2416.
    PubMed     Abstract available


  61. KURTH T, Rist PM, Ridker PM, Kotler G, et al
    Association of Migraine With Aura and Other Risk Factors With Incident Cardiovascular Disease in Women.
    JAMA. 2020;323:2281-2289.
    PubMed     Abstract available


    May 2020
  62. HIRSCH IB, Gaudiani LM
    Using Insulin to Treat Poorly Controlled Type 2 Diabetes in 2020.
    JAMA. 2020 May 22. pii: 2766597. doi: 10.1001/jama.2020.1303.
    PubMed    


  63. CROSS SH, Mehra MR, Bhatt DL, Nasir K, et al
    Rural-Urban Differences in Cardiovascular Mortality in the US, 1999-2017.
    JAMA. 2020;323:1852-1854.
    PubMed    


    April 2020
  64. HONIGBERG MC, Natarajan P
    Premature Menopause and Risk for Cardiovascular Disease-Reply.
    JAMA. 2020;323:1617-1618.
    PubMed    


  65. SCARABIN PY
    Premature Menopause and Risk for Cardiovascular Disease.
    JAMA. 2020;323:1616.
    PubMed    


  66. ZHOU X, Tang G
    Premature Menopause and Risk for Cardiovascular Disease.
    JAMA. 2020;323:1616-1617.
    PubMed    


  67. HAMPTON T
    After Heart Attack, Growth Factor Improves Scar Quality and Heart Function in Pig Study.
    JAMA. 2020;323:1235.
    PubMed    


    March 2020
  68. PETRIE MC, Verma S, Docherty KF, Inzucchi SE, et al
    Effect of Dapagliflozin on Worsening Heart Failure and Cardiovascular Death in Patients With Heart Failure With and Without Diabetes.
    JAMA. 2020 Mar 27. pii: 2763950. doi: 10.1001/jama.2020.1906.
    PubMed     Abstract available


  69. PLUTZKY J
    Epigenetic Therapeutics for Cardiovascular Disease: Writing, Erasing, Reading, and Maybe Forgetting.
    JAMA. 2020 Mar 27. pii: 2763949. doi: 10.1001/jama.2020.3298.
    PubMed    


  70. RAY KK, Nicholls SJ, Buhr KA, Ginsberg HN, et al
    Effect of Apabetalone Added to Standard Therapy on Major Adverse Cardiovascular Events in Patients With Recent Acute Coronary Syndrome and Type 2 Diabetes: A Randomized Clinical Trial.
    JAMA. 2020 Mar 27. pii: 2763951. doi: 10.1001/jama.2020.3308.
    PubMed     Abstract available


  71. ABBASI J
    Cardiovascular Corner-Stable Coronary Artery Disease, An LDL "Vaccine," and Anti-inflammatories.
    JAMA. 2020 Mar 18. pii: 2763421. doi: 10.1001/jama.2019.20983.
    PubMed    


    February 2020
  72. LOPES RD, de Barros E Silva PGM, Damiani LP, Santos RHN, et al
    Major Adverse Cardiovascular Events After 12 Months Among Patients With Acute Coronary Syndrome Receiving Loading Doses of Atorvastatin Prior to Planned PCI.
    JAMA. 2020;323:787-789.
    PubMed    


  73. THIELE H, Desch S, Freund A
    Microaxial Left Ventricular Assist Devices: In Search of an Appropriate Indication.
    JAMA. 2020;323:716-718.
    PubMed    


  74. CAMPBELL BCV, Mitchell PJ, Churilov L, Yassi N, et al
    Effect of Intravenous Tenecteplase Dose on Cerebral Reperfusion Before Thrombectomy in Patients With Large Vessel Occlusion Ischemic Stroke: The EXTEND-IA TNK Part 2 Randomized Clinical Trial.
    JAMA. 2020 Feb 20. pii: 2761799. doi: 10.1001/jama.2020.1511.
    PubMed     Abstract available


  75. MOSLEY JD, Gupta DK, Tan J, Yao J, et al
    Predictive Accuracy of a Polygenic Risk Score Compared With a Clinical Risk Score for Incident Coronary Heart Disease.
    JAMA. 2020;323:627-635.
    PubMed     Abstract available


  76. PETERS AT, Mutharasan RK
    Aspirin for Prevention of Cardiovascular Disease.
    JAMA. 2020;323:676.
    PubMed    


  77. ELLIOTT J, Bodinier B, Bond TA, Chadeau-Hyam M, et al
    Predictive Accuracy of a Polygenic Risk Score-Enhanced Prediction Model vs a Clinical Risk Score for Coronary Artery Disease.
    JAMA. 2020;323:636-645.
    PubMed     Abstract available


  78. KHAN SS, Cooper R, Greenland P
    Do Polygenic Risk Scores Improve Patient Selection for Prevention of Coronary Artery Disease?
    JAMA. 2020;323:614-615.
    PubMed    


  79. DHRUVA SS, Ross JS, Mortazavi BJ, Hurley NC, et al
    Association of Use of an Intravascular Microaxial Left Ventricular Assist Device vs Intra-aortic Balloon Pump With In-Hospital Mortality and Major Bleeding Among Patients With Acute Myocardial Infarction Complicated by Cardiogenic Shock.
    JAMA. 2020 Feb 10. pii: 2761003. doi: 10.1001/jama.2020.0254.
    PubMed     Abstract available


    January 2020
  80. MCEVOY JW, Daya N, Rahman F, Hoogeveen RC, et al
    Association of Isolated Diastolic Hypertension as Defined by the 2017 ACC/AHA Blood Pressure Guideline With Incident Cardiovascular Outcomes.
    JAMA. 2020;323:329-338.
    PubMed     Abstract available


    December 2019
  81. YANG WY, Zhang ZY, Staessen JA
    Blood Pressure Indexes Associated With Mortality and Cardiovascular Outcomes-Reply.
    JAMA. 2019;322:2343-2344.
    PubMed    


  82. HUANG Y, Kuang J, Mai W
    Blood Pressure Indexes Associated With Mortality and Cardiovascular Outcomes.
    JAMA. 2019;322:2342-2343.
    PubMed    


    November 2019
  83. SLOMSKI A
    Polypill More Effective Than Usual Care for Reducing Cardiovascular Risks.
    JAMA. 2019;322:1948.
    PubMed    


  84. HUFFMAN MD, Salam A, Patel A
    Implementation Strategies for Cardiovascular Polypills.
    JAMA. 2019 Nov 25. pii: 2756238. doi: 10.1001/jama.2019.18102.
    PubMed    


  85. JOYNER MJ, Paneth N
    Cardiovascular Disease Prevention at a Crossroads:: Precision Medicine or Polypill?
    JAMA. 2019 Nov 25. pii: 2756239. doi: 10.1001/jama.2019.19026.
    PubMed    


  86. BAIREY MERZ CN
    Testing for Coronary Microvascular Dysfunction.
    JAMA. 2019 Nov 18. pii: 2755842. doi: 10.1001/jama.2019.16625.
    PubMed    


  87. WEI J, Cheng S, Merz CNB
    Coronary Microvascular Dysfunction Causing Cardiac Ischemia in Women.
    JAMA. 2019 Nov 18. pii: 2755840. doi: 10.1001/jama.2019.15736.
    PubMed    


  88. HONIGBERG MC, Zekavat SM, Aragam K, Finneran P, et al
    Association of Premature Natural and Surgical Menopause With Incident Cardiovascular Disease.
    JAMA. 2019 Nov 18. pii: 2755841. doi: 10.1001/jama.2019.19191.
    PubMed     Abstract available


  89. GOLDBERG AC, Leiter LA, Stroes ESG, Baum SJ, et al
    Effect of Bempedoic Acid vs Placebo Added to Maximally Tolerated Statins on Low-Density Lipoprotein Cholesterol in Patients at High Risk for Cardiovascular Disease: The CLEAR Wisdom Randomized Clinical Trial.
    JAMA. 2019;322:1780-1788.
    PubMed     Abstract available


  90. MEIJERS WC, Moslehi JJ
    Need for Multidisciplinary Research and Data-Driven Guidelines for the Cardiovascular Care of Patients With Cancer.
    JAMA. 2019;322:1775-1776.
    PubMed    


  91. WATANABE H, Kimura T
    1 vs 12 Months of Dual Antiplatelet Therapy for Patients After Percutaneous Coronary Intervention-Reply.
    JAMA. 2019;322:1715-1716.
    PubMed    


  92. TAN WK
    One vs 12 Months of Dual Antiplatelet Therapy for Patients After Percutaneous Coronary Intervention.
    JAMA. 2019;322:1715.
    PubMed    


    October 2019
  93. HAHN JY, Song YB, Gwon HC
    P2Y12 Inhibitor Monotherapy vs Dual Antiplatelet Therapy After Percutaneous Coronary Intervention-Reply.
    JAMA. 2019;322:1607-1608.
    PubMed    


  94. MCCAW ZR, Wei LJ
    P2Y12 Inhibitor Monotherapy vs Dual Antiplatelet Therapy After Percutaneous Coronary Intervention.
    JAMA. 2019;322:1607.
    PubMed    


  95. MORRIS NB, Gruss F, Lempert S, English T, et al
    A Preliminary Study of the Effect of Dousing and Foot Immersion on Cardiovascular and Thermal Responses to Extreme Heat.
    JAMA. 2019;322:1411-1413.
    PubMed    


  96. JAIN A, Davis AM
    Primary Prevention of Cardiovascular Disease.
    JAMA. 2019 Oct 4:1-3. doi: 10.1001/jama.2019.15915.
    PubMed    


    September 2019
  97. WEXLER DJ
    Sulfonylureas and Cardiovascular Safety: The Final Verdict?
    JAMA. 2019 Sep 19. pii: 2751396. doi: 10.1001/jama.2019.14533.
    PubMed    


  98. ROUMIE CL, Chipman J, Min JY, Hackstadt AJ, et al
    Association of Treatment With Metformin vs Sulfonylurea With Major Adverse Cardiovascular Events Among Patients With Diabetes and Reduced Kidney Function.
    JAMA. 2019 Sep 19:1-11. doi: 10.1001/jama.2019.13206.
    PubMed     Abstract available


  99. ROSENSTOCK J, Kahn SE, Johansen OE, Zinman B, et al
    Effect of Linagliptin vs Glimepiride on Major Adverse Cardiovascular Outcomes in Patients With Type 2 Diabetes: The CAROLINA Randomized Clinical Trial.
    JAMA. 2019 Sep 19. pii: 2751398. doi: 10.1001/jama.2019.13772.
    PubMed     Abstract available


  100. ABBASI J
    Cardiovascular Corner: Prescription Omega-3s, Stroke Rehab, and Statins After Age 75.
    JAMA. 2019 Sep 11. pii: 2751407. doi: 10.1001/jama.2019.14485.
    PubMed    


  101. FERENCE BA, Bhatt DL, Catapano AL, Packard CJ, et al
    Association of Genetic Variants Related to Combined Exposure to Lower Low-Density Lipoproteins and Lower Systolic Blood Pressure With Lifetime Risk of Cardiovascular Disease.
    JAMA. 2019 Sep 2. pii: 2749533. doi: 10.1001/jama.2019.14120.
    PubMed     Abstract available


  102. AMINIAN A, Zajichek A, Arterburn DE, Wolski KE, et al
    Association of Metabolic Surgery With Major Adverse Cardiovascular Outcomes in Patients With Type 2 Diabetes and Obesity.
    JAMA. 2019 Sep 2. pii: 2749478. doi: 10.1001/jama.2019.14231.
    PubMed     Abstract available


    August 2019
  103. DUNCAN MS, Freiberg MS, Greevy RA Jr, Kundu S, et al
    Association of Smoking Cessation With Subsequent Risk of Cardiovascular Disease.
    JAMA. 2019;322:642-650.
    PubMed     Abstract available


  104. COLE TB
    Smoking Cessation and Reduction of Cardiovascular Disease Risk.
    JAMA. 2019;322:651.
    PubMed    


  105. YANG WY, Melgarejo JD, Thijs L, Zhang ZY, et al
    Association of Office and Ambulatory Blood Pressure With Mortality and Cardiovascular Outcomes.
    JAMA. 2019;322:409-420.
    PubMed     Abstract available


  106. ZHONG VW, Van Horn L, Allen NB
    Dietary Cholesterol or Egg Consumption and Cardiovascular Outcomes-Reply.
    JAMA. 2019;322:467.
    PubMed    


  107. KEYSERLING TC, Berkowitz SA, Samuel-Hodge CD
    Dietary Cholesterol or Egg Consumption and Cardiovascular Outcomes.
    JAMA. 2019;322:466-467.
    PubMed    


    July 2019
  108. JAHAN R, Saver JL, Schwamm LH, Fonarow GC, et al
    Association Between Time to Treatment With Endovascular Reperfusion Therapy and Outcomes in Patients With Acute Ischemic Stroke Treated in Clinical Practice.
    JAMA. 2019;322:252-263.
    PubMed     Abstract available


    June 2019
  109. HAHN JY, Song YB, Oh JH, Chun WJ, et al
    Effect of P2Y12 Inhibitor Monotherapy vs Dual Antiplatelet Therapy on Cardiovascular Events in Patients Undergoing Percutaneous Coronary Intervention: The SMART-CHOICE Randomized Clinical Trial.
    JAMA. 2019;321:2428-2437.
    PubMed     Abstract available


  110. WATANABE H, Domei T, Morimoto T, Natsuaki M, et al
    Effect of 1-Month Dual Antiplatelet Therapy Followed by Clopidogrel vs 12-Month Dual Antiplatelet Therapy on Cardiovascular and Bleeding Events in Patients Receiving PCI: The STOPDAPT-2 Randomized Clinical Trial.
    JAMA. 2019;321:2414-2427.
    PubMed     Abstract available


  111. ABBASI J
    Cardiovascular Corner: Low Lipids, Metformin, and Plant-Based Diets.
    JAMA. 2019 Jun 12. pii: 2736162. doi: 10.1001/jama.2019.6544.
    PubMed    


  112. ZHENG SL, Roddick AJ
    Meta-analysis of Aspirin for Primary Prevention of Cardiovascular Events-Reply.
    JAMA. 2019;321:2244-2245.
    PubMed    


  113. SHAH R
    Meta-analysis of Aspirin for Primary Prevention of Cardiovascular Events.
    JAMA. 2019;321:2244.
    PubMed    


  114. SYN NL, Wee IJY
    Meta-analysis of Aspirin for Primary Prevention of Cardiovascular Events.
    JAMA. 2019;321:2243-2244.
    PubMed    


    May 2019
  115. BERRY C, McCartney PJ, Maznyczka AM
    Fibrinolytic Therapy to Reduce Microvascular Obstruction After Myocardial Infarction-Reply.
    JAMA. 2019;321:2033-2034.
    PubMed    


  116. ALKHALIL M
    Fibrinolytic Therapy to Reduce Microvascular Obstruction After Myocardial Infarction.
    JAMA. 2019;321:2032-2033.
    PubMed    


  117. SEZER M, Umman S
    Fibrinolytic Therapy to Reduce Microvascular Obstruction After Myocardial Infarction.
    JAMA. 2019;321:2032.
    PubMed    


  118. CHAN MTV, Wang CY, Seet E, Tam S, et al
    Association of Unrecognized Obstructive Sleep Apnea With Postoperative Cardiovascular Events in Patients Undergoing Major Noncardiac Surgery.
    JAMA. 2019;321:1788-1798.
    PubMed     Abstract available


  119. AUCKLEY D, Memtsoudis S
    Unrecognized Obstructive Sleep Apnea and Postoperative Cardiovascular Complications: A Wake-up Call.
    JAMA. 2019;321:1774-1776.
    PubMed    


  120. WISE RA, Chapman KR, Scirica BM, Bhatt DL, et al
    Effect of Aclidinium Bromide on Major Cardiovascular Events and Exacerbations in High-Risk Patients With Chronic Obstructive Pulmonary Disease: The ASCENT-COPD Randomized Clinical Trial.
    JAMA. 2019;321:1693-1701.
    PubMed     Abstract available



  121. Cardiovascular Benefits of SGLT2 Inhibitors and GLP-1 Receptor Agonists in Type 2 Diabetes.
    JAMA. 2019;321:1720-1721.
    PubMed    


    April 2019
  122. GREGG EW, Hora I, Benoit SR
    Resurgence in Diabetes-Related Complications.
    JAMA. 2019 Apr 15. pii: 2730953. doi: 10.1001/jama.2019.3471.
    PubMed    


  123. YANO Y, Muntner P, Lloyd-Jones D
    Hypertension in Young Adults and Subsequent Cardiovascular Disease-Reply.
    JAMA. 2019;321:1310-1311.
    PubMed    


  124. DE KOUCHKOVSKY I, Mayfield J, Kohlwes J
    Hypertension in Young Adults and Subsequent Cardiovascular Disease.
    JAMA. 2019;321:1310.
    PubMed    


    March 2019
  125. ZHONG VW, Van Horn L, Cornelis MC, Wilkins JT, et al
    Associations of Dietary Cholesterol or Egg Consumption With Incident Cardiovascular Disease and Mortality.
    JAMA. 2019;321:1081-1095.
    PubMed     Abstract available


  126. BONOW RO, Braunwald E
    The Evidence Supporting Cardiovascular Guidelines: Is There Evidence of Progress in the Last Decade?
    JAMA. 2019;321:1053-1054.
    PubMed    


  127. ECKEL RH
    Reconsidering the Importance of the Association of Egg Consumption and Dietary Cholesterol With Cardiovascular Disease Risk.
    JAMA. 2019;321:1055-1056.
    PubMed    


    February 2019
  128. HANEUSE S, VanderWeele TJ, Arterburn D
    Using the E-Value to Assess the Potential Effect of Unmeasured Confounding in Observational Studies.
    JAMA. 2019;321:602-603.
    PubMed    


    January 2019
  129. FERENCE BA, Kastelein JJP, Ray KK, Ginsberg HN, et al
    Association of Triglyceride-Lowering LPL Variants and LDL-C-Lowering LDLR Variants With Risk of Coronary Heart Disease.
    JAMA. 2019;321:364-373.
    PubMed     Abstract available


  130. NAVAR AM
    The Evolving Story of Triglycerides and Coronary Heart Disease Risk.
    JAMA. 2019;321:347-349.
    PubMed    


  131. ZHENG SL, Roddick AJ
    Association of Aspirin Use for Primary Prevention With Cardiovascular Events and Bleeding Events: A Systematic Review and Meta-analysis.
    JAMA. 2019;321:277-287.
    PubMed     Abstract available


  132. MCCARTNEY PJ, Eteiba H, Maznyczka AM, McEntegart M, et al
    Effect of Low-Dose Intracoronary Alteplase During Primary Percutaneous Coronary Intervention on Microvascular Obstruction in Patients With Acute Myocardial Infarction: A Randomized Clinical Trial.
    JAMA. 2019;321:56-68.
    PubMed     Abstract available


  133. WANG TY, Kaltenbach LA, Cannon CP, Fonarow GC, et al
    Effect of Medication Co-payment Vouchers on P2Y12 Inhibitor Use and Major Adverse Cardiovascular Events Among Patients With Myocardial Infarction: The ARTEMIS Randomized Clinical Trial.
    JAMA. 2019;321:44-55.
    PubMed     Abstract available


  134. JACKEVICIUS CA, Ko DT
    Medication Co-payment Vouchers, Adherence With Antiplatelet Therapy, and Adverse Cardiovascular Events After Myocardial Infarction.
    JAMA. 2019;321:37-39.
    PubMed    


    December 2018
  135. LOTTA LA, Wittemans LBL, Zuber V, Stewart ID, et al
    Association of Genetic Variants Related to Gluteofemoral vs Abdominal Fat Distribution With Type 2 Diabetes, Coronary Disease, and Cardiovascular Risk Factors.
    JAMA. 2018;320:2553-2563.
    PubMed     Abstract available


  136. WADHERA RK, Joynt Maddox KE, Wasfy JH, Haneuse S, et al
    Association of the Hospital Readmissions Reduction Program With Mortality Among Medicare Beneficiaries Hospitalized for Heart Failure, Acute Myocardial Infarction, and Pneumonia.
    JAMA. 2018;320:2542-2552.
    PubMed     Abstract available


  137. FONAROW GC
    Unintended Harm Associated With the Hospital Readmissions Reduction Program.
    JAMA. 2018;320:2539-2541.
    PubMed    


  138. SAMIERI C, Empana JP
    Cardiovascular Health and Cognitive Decline-Reply.
    JAMA. 2018;320:2483-2484.
    PubMed    


  139. HOWLAND RH
    Cardiovascular Health and Cognitive Decline.
    JAMA. 2018;320:2483.
    PubMed    


    November 2018
  140. KIM JM, Stewart R, Yoon JS
    Cardiac Outcomes After Treatment for Depression in Patients With Acute Coronary Syndrome-Reply.
    JAMA. 2018;320:2152-2153.
    PubMed    


  141. RUST G
    Cardiac Outcomes After Treatment for Depression in Patients With Acute Coronary Syndrome.
    JAMA. 2018;320:2152.
    PubMed    


  142. ZIMMERMANN FM, El Farissi M, Tonino PAL
    Cardiac Outcomes After Treatment for Depression in Patients With Acute Coronary Syndrome.
    JAMA. 2018;320:2151-2152.
    PubMed    


  143. THOMBS BD, Ziegelstein RC
    Cardiac Outcomes After Treatment for Depression in Patients With Acute Coronary Syndrome.
    JAMA. 2018;320:2151.
    PubMed    


  144. ROSENSTOCK J, Perkovic V, Johansen OE, Cooper ME, et al
    Effect of Linagliptin vs Placebo on Major Cardiovascular Events in Adults With Type 2 Diabetes and High Cardiovascular and Renal Risk: The CARMELINA Randomized Clinical Trial.
    JAMA. 2018 Nov 9. pii: 2714646. doi: 10.1001/jama.2018.18269.
    PubMed     Abstract available


  145. VAN SLOTEN TT, Tafflet M, Perier MC, Dugravot A, et al
    Association of Change in Cardiovascular Risk Factors With Incident Cardiovascular Events.
    JAMA. 2018;320:1793-1804.
    PubMed     Abstract available


  146. SON JS, Choi S, Kim K, Kim SM, et al
    Association of Blood Pressure Classification in Korean Young Adults According to the 2017 American College of Cardiology/American Heart Association Guidelines With Subsequent Cardiovascular Disease Events.
    JAMA. 2018;320:1783-1792.
    PubMed     Abstract available


  147. YANO Y, Reis JP, Colangelo LA, Shimbo D, et al
    Association of Blood Pressure Classification in Young Adults Using the 2017 American College of Cardiology/American Heart Association Blood Pressure Guideline With Cardiovascular Events Later in Life.
    JAMA. 2018;320:1774-1782.
    PubMed     Abstract available


  148. VASAN RS
    High Blood Pressure in Young Adulthood and Risk of Premature Cardiovascular Disease: Calibrating Treatment Benefits to Potential Harm.
    JAMA. 2018;320:1760-1763.
    PubMed    


    October 2018
  149. SLOMSKI A
    No Cardiovascular Protection From Omega-3 Fatty Acids.
    JAMA. 2018;320:1631.
    PubMed    


  150. ABBASI J
    To Prevent Cardiovascular Disease, Pay Attention to Pregnancy Complications.
    JAMA. 2018 Oct 17. pii: 2708197. doi: 10.1001/jama.2018.14645.
    PubMed    


  151. VOELKER R
    Device Approved to Seal Coronary Artery Perforations.
    JAMA. 2018;320:1528.
    PubMed    


  152. FISHER DP, Johnson E, Haneuse S, Arterburn D, et al
    Association Between Bariatric Surgery and Macrovascular Disease Outcomes in Patients With Type 2 Diabetes and Severe Obesity.
    JAMA. 2018;320:1570-1582.
    PubMed     Abstract available


  153. ABBASI J
    Researchers Test New Techniques to Rule Out and Predict Heart Attacks.
    JAMA. 2018;320:1425.
    PubMed    


    September 2018
  154. BHATT DL
    Fractional Flow Reserve Measurement for the Physiological Assessment of Coronary Artery Stenosis Severity.
    JAMA. 2018;320:1275-1276.
    PubMed    


  155. FRIEDRICH MJ
    Cardiovascular Disease in India.
    JAMA. 2018;320:1097.
    PubMed    


  156. ZHU Y, Zhao Q
    Antiplatelet Therapy After Coronary Artery Bypass Grafting-Reply.
    JAMA. 2018;320:1036-1037.
    PubMed    


  157. SHAH R, Hesterberg K
    Antiplatelet Therapy After Coronary Artery Bypass Grafting.
    JAMA. 2018;320:1035.
    PubMed    


  158. MORI M, Geirsson A
    Antiplatelet Therapy After Coronary Artery Bypass Grafting.
    JAMA. 2018;320:1035-1036.
    PubMed    


  159. WRIGHT JS, Wall HK, Ritchey MD
    Million Hearts 2022: Small Steps Are Needed for Cardiovascular Disease Prevention.
    JAMA. 2018 Sep 6. pii: 2702070. doi: 10.1001/jama.2018.13326.
    PubMed    


    August 2018
  160. WILLIAMSON W, Lewandowski AJ, Forkert ND, Griffanti L, et al
    Association of Cardiovascular Risk Factors With MRI Indices of Cerebrovascular Structure and Function and White Matter Hyperintensities in Young Adults.
    JAMA. 2018;320:665-673.
    PubMed     Abstract available


  161. SAMIERI C, Perier MC, Gaye B, Proust-Lima C, et al
    Association of Cardiovascular Health Level in Older Age With Cognitive Decline and Incident Dementia.
    JAMA. 2018;320:657-664.
    PubMed     Abstract available


  162. SAVER JL, Cushman M
    Striving for Ideal Cardiovascular and Brain Health: It Is Never Too Early or Too Late.
    JAMA. 2018;320:645-647.
    PubMed    


    July 2018
  163. DONADINI MP, Bellesini M, Squizzato A
    Aspirin Plus Clopidogrel vs Aspirin Alone for Preventing Cardiovascular Events Among Patients at High Risk for Cardiovascular Events.
    JAMA. 2018 Jul 26. pii: 2695067. doi: 10.1001/jama.2018.9641.
    PubMed     Abstract available


  164. KIM JM, Stewart R, Lee YS, Lee HJ, et al
    Effect of Escitalopram vs Placebo Treatment for Depression on Long-term Cardiac Outcomes in Patients With Acute Coronary Syndrome: A Randomized Clinical Trial.
    JAMA. 2018;320:350-358.
    PubMed     Abstract available


  165. RUBIN R
    Red Meat Allergy Associated With Coronary Artery Plaque.
    JAMA. 2018;320:331.
    PubMed    


  166. JIN J
    Risk Assessment for Cardiovascular Disease With Nontraditional Risk Factors.
    JAMA. 2018;320:316.
    PubMed    


  167. WILKINS JT, Lloyd-Jones DM
    USPSTF Recommendations for Assessment of Cardiovascular Risk With Nontraditional Risk Factors: Finding the Right Tests for the Right Patients.
    JAMA. 2018 Jul 10. pii: 2687223. doi: 10.1001/jama.2018.9346.
    PubMed    


  168. CURRY SJ, Krist AH, Owens DK, Barry MJ, et al
    Screening for Peripheral Artery Disease and Cardiovascular Disease Risk Assessment With the Ankle-Brachial Index: US Preventive Services Task Force Recommendation Statement.
    JAMA. 2018;320:177-183.
    PubMed     Abstract available


  169. LIN JS, Evans CV, Johnson E, Redmond N, et al
    Nontraditional Risk Factors in Cardiovascular Disease Risk Assessment: Updated Evidence Report and Systematic Review for the US Preventive Services Task Force.
    JAMA. 2018 Jul 10. pii: 2687224. doi: 10.1001/jama.2018.4242.
    PubMed     Abstract available


  170. CURRY SJ, Krist AH, Owens DK, Barry MJ, et al
    Risk Assessment for Cardiovascular Disease With Nontraditional Risk Factors: US Preventive Services Task Force Recommendation Statement.
    JAMA. 2018 Jul 10. pii: 2687225. doi: 10.1001/jama.2018.8359.
    PubMed     Abstract available


    June 2018
  171. SELAK V, Kerr A, Poppe K, Wu B, et al
    Annual Risk of Major Bleeding Among Persons Without Cardiovascular Disease Not Receiving Antiplatelet Therapy.
    JAMA. 2018;319:2507-2520.
    PubMed     Abstract available


  172. JONAS DE, Reddy S, Middleton JC, Barclay C, et al
    Screening for Cardiovascular Disease Risk With Resting or Exercise Electrocardiography: Evidence Report and Systematic Review for the US Preventive Services Task Force.
    JAMA. 2018;319:2315-2328.
    PubMed     Abstract available


  173. CURRY SJ, Krist AH, Owens DK, Barry MJ, et al
    Screening for Cardiovascular Disease Risk With Electrocardiography: US Preventive Services Task Force Recommendation Statement.
    JAMA. 2018;319:2308-2314.
    PubMed     Abstract available


  174. JIN J
    Screening for Cardiovascular Disease Risk With ECG.
    JAMA. 2018;319:2346.
    PubMed    


  175. MCCARTHY CP, Vaduganathan M, Januzzi JL Jr
    Type 2 Myocardial Infarction-Diagnosis, Prognosis, and Treatment.
    JAMA. 2018 Jun 11. pii: 2684931. doi: 10.1001/jama.2018.7125.
    PubMed    


  176. MERCHANT FM, Dickert NW Jr, Howard DH
    Mandatory Shared Decision Making by the Centers for Medicare & Medicaid Services for Cardiovascular Procedures and Other Tests.
    JAMA. 2018 Jun 4. pii: 2683805. doi: 10.1001/jama.2018.6617.
    PubMed    


    May 2018
  177. BHATT DL
    Percutaneous Coronary Intervention in 2018.
    JAMA. 2018;319:2127-2128.
    PubMed    


  178. ABBASI J
    Another Nail in the Coffin for Fish Oil Supplements.
    JAMA. 2018;319:1851-1852.
    PubMed    


    April 2018
  179. ZHAO Q, Zhu Y, Xu Z, Cheng Z, et al
    Effect of Ticagrelor Plus Aspirin, Ticagrelor Alone, or Aspirin Alone on Saphenous Vein Graft Patency 1 Year After Coronary Artery Bypass Grafting: A Randomized Clinical Trial.
    JAMA. 2018;319:1677-1686.
    PubMed     Abstract available


  180. ALEXANDER JH
    Ticagrelor Following Coronary Artery Bypass Grafting: For Better Vein Graft Patency or Better Patient Outcomes?
    JAMA. 2018;319:1661-1662.
    PubMed    


  181. NAVARESE EP, Robinson JG, Kowalewski M, Kolodziejczak M, et al
    Association Between Baseline LDL-C Level and Total and Cardiovascular Mortality After LDL-C Lowering: A Systematic Review and Meta-analysis.
    JAMA. 2018;319:1566-1579.
    PubMed     Abstract available


  182. ABBASI J
    Using Heart Pump Data to Manage Cardiogenic Shock.
    JAMA. 2018;319:1427.
    PubMed    


  183. YU K, Qiu G, Chan KH, Lam KH, et al
    Association of Solid Fuel Use With Risk of Cardiovascular and All-Cause Mortality in Rural China.
    JAMA. 2018;319:1351-1361.
    PubMed     Abstract available


    March 2018
  184. GUPTA A, Das SR, Pandey A
    beta-Blockers in Myocardial Infarction: Issues With Standard Admission Order Sets.
    JAMA. 2018;319:1269-1270.
    PubMed    


  185. BERWANGER O, Santucci EV, de Barros E Silva PGM, Jesuino IA, et al
    Effect of Loading Dose of Atorvastatin Prior to Planned Percutaneous Coronary Intervention on Major Adverse Cardiovascular Events in Acute Coronary Syndrome: The SECURE-PCI Randomized Clinical Trial.
    JAMA. 2018 Mar 11. pii: 2675023. doi: 10.1001/jama.2018.2444.
    PubMed     Abstract available


  186. NICHOLLS SJ, Psaltis PJ
    Lipid Lowering in Acute Coronary Syndrome: Is Treatment Early Enough?
    JAMA. 2018 Mar 11. pii: 2675022. doi: 10.1001/jama.2018.2426.
    PubMed    


  187. ABBASI J
    Do All Patients Need beta-Blockers After a Heart Attack?
    JAMA. 2018;319:853-855.
    PubMed    


    February 2018
  188. HUFFMAN MD, Mohanan PP, Devarajan R, Baldridge AS, et al
    Effect of a Quality Improvement Intervention on Clinical Outcomes in Patients in India With Acute Myocardial Infarction: The ACS QUIK Randomized Clinical Trial.
    JAMA. 2018;319:567-578.
    PubMed     Abstract available


    January 2018
  189. WADHERA RK, Yeh RW, Joynt Maddox KE
    The Rise and Fall of Mandatory Cardiac Bundled Payments.
    JAMA. 2018;319:335-336.
    PubMed    


  190. KENNEDY AB, Lavie CJ, Blair SN
    Fitness or Fatness: Which Is More Important?
    JAMA. 2018;319:231-232.
    PubMed    


    December 2017
  191. GREENLAND P
    Cardiovascular Guideline Skepticism vs Lifestyle Realism?
    JAMA. 2017 Dec 14. pii: 2666625. doi: 10.1001/jama.2017.19675.
    PubMed    


    November 2017
  192. SLOMSKI A
    Evolocumab Reduces Cardiovascular Risk Regardless of Diabetes Status.
    JAMA. 2017;318:1968.
    PubMed    


  193. EMDIN CA, Khera AV, Kathiresan S
    Mendelian Randomization.
    JAMA. 2017;318:1925-1926.
    PubMed    


  194. IRONY TZ
    The "Utility" in Composite Outcome Measures: Measuring What Is Important to Patients.
    JAMA. 2017;318:1820-1821.
    PubMed    


  195. CHAPMAN AR, Lee KK, McAllister DA, Cullen L, et al
    Association of High-Sensitivity Cardiac Troponin I Concentration With Cardiac Outcomes in Patients With Suspected Acute Coronary Syndrome.
    JAMA. 2017 Nov 11. doi: 10.1001/jama.2017.17488.
    PubMed     Abstract available


    October 2017
  196. ABBASI J
    Could a New Method to Detect Coronary Inflammation Prevent Heart Attacks?
    JAMA. 2017;318:1527-1528.
    PubMed    


    September 2017
  197. WADHERA RK, Bhatt DL
    Taking the "Public" Out of Public Reporting of Percutaneous Coronary Intervention.
    JAMA. 2017 Sep 28. doi: 10.1001/jama.2017.12087.
    PubMed    


  198. LICHTMAN JH, Jones MR, Leifheit EC, Sheffet AJ, et al
    Carotid Endarterectomy and Carotid Artery Stenting in the US Medicare Population, 1999-2014.
    JAMA. 2017;318:1035-1046.
    PubMed     Abstract available


  199. BARNARD ND, Willett WC, Ding EL
    The Misuse of Meta-analysis in Nutrition Research.
    JAMA. 2017 Sep 18. doi: 10.1001/jama.2017.12083.
    PubMed    


  200. DEVEREAUX PJ, Biccard BM, Chan MTV
    High-Sensitivity Troponin Levels, Ischemia, and Mortality-Reply.
    JAMA. 2017;318:865.
    PubMed    


  201. SMILOWITZ NR
    High-Sensitivity Troponin Levels, Ischemia, and Mortality.
    JAMA. 2017;318:864-865.
    PubMed    


    August 2017
  202. KRUMHOLZ HM
    Treatment of Cholesterol in 2017.
    JAMA. 2017;318:417-418.
    PubMed    


Thank you for your interest in scientific medicine.


AMEDEO Ischemic Heart Disease is free of charge.
This policy is made possible thanks to a media sponsorship by Boehringer Ingelheim.

Design: